 | | Vol. 7.12 – 11 April, 2022 |
| |
|
|
| Investigators reported a chemical cocktail of five small molecules that promoted adult cardiomyocyte proliferation and heart regeneration.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Phenotypic and metabolic profiles with associated cellular signaling pathways involved in lipid metabolism were investigated in the mice heart and human cardiomyocytes to establish treatment effect of adiponectin’s agonists.
[Cell Death & Disease] |
|
|
|
| Researchers evaluated the impact of autophagy modulation by different pharmacological/genetic approaches on the viability and phenotype of murine cardiac stromal cells subjected to nutrient deprivation or hyperglycemia, in order to mimic relevant stress conditions and risk factors of cardiovascular diseases.
[Cell Death Discovery] |
|
|
|
| Scientists confirmed that lipopolysaccharides significantly enhanced the expression of islet cell autoantigen 69 (ICA69) in wild-type mice, macrophages, and cardiomyocytes.
[Cell Death Discovery] |
|
|
|
| To understand the interplay between cardiomyocyte and nonmyocyte cell types in human hypertrophic cardiomyopathy (HCM), single nuclei RNA-sequencing was performed on myectomy specimens from HCM patients with left ventricular outflow tract obstruction and control samples from donor hearts free of cardiovascular disease.
[Scientific Reports] |
|
|
|
| | Investigators undertook an integrative multiomics approach to delineate the process of induced myogenic progenitor cells reprogramming in comparison to myogenic transdifferentiation mediated solely by MyoD.
[Science Advances] |
|
|
|
| The authors described that Piezo1, a mechanosensitive ion channel, kept skeletal muscle stem cells in a quiescent state and prevented senescence.
[Redox Biology] |
|
|
|
|
Researchers developed a multifactor-based protocol that combined adenovector-mediated MYOD expression, small molecule inhibitor and growth factor treatment, and electrical pulse stimulation to efficiently reprogram different types of human-derived multipotent stem cells into physiologically functional skeletal muscle cells.
[Cellular and Molecular Life Sciences] |
| | The authors performed quantitative real-time PCR to evaluate the stability of expression of candidate internal reference genes in skeletal muscle-derived satellite cells at 0, 12, 24, 36 and 48 hours of growth and after differentiation for 0, 2, 4, 6 and 8 days.
[Scientific Reports] |
| |
|
|
| Researchers demonstrated that a positive correlation of protein arginine methyltransferase 5 (PRMT5) expression and trimethylamine N-oxide (TMAO)-induced vascular inflammation, with upregulated vascular cell adhesion molecule-1 expression in primary rat and human vascular smooth muscle cells in vitro.
[Cell Death & Disease] |
|
|
|
| The authors investigated the role of lipid phosphate phosphatase 3 and lysophospholipid signaling in a well-defined model of pathologic aortic injury.
[Scientific Reports] |
|
|
|
| Scientists deciphered the role of the lncRNA antisense noncoding RNA in the INK4 locus in airway smooth muscle cell proliferation, migration and extracellular matrix deposition.
[Kaohsiung Journal of Medical Sciences] |
|
|
|
| Researchers investigated the effect of circLDLR on the proliferation and apoptosis of vascular smooth muscle cells in coronary artery disease and its regulatory mechanism.
[Journal of Cardiovascular Pharmacology] |
|  |
|
|
|
| Unravelling the molecular mechanisms underlying electropathology is expected to fuel the development of innovative personalized diagnostic tools and mechanism-based therapies for atrial fibrillation.
[Nature Reviews Disease Primers] |
|
|
|
| The embryonic development process and the pro-myogenic role of the muscle-resident cell populations in co-cultures are described, highlighting the possible clinical applications of induced pluripotent stem cells (iPSCs) in the skeletal muscle tissue engineering field.
[NPJ Regenerative Medicine] |
|
|
|
|
| PepGen, Inc. announced a critical clinical milestone for PGN-EDO51, the company’s lead product candidate for the treatment of Duchenne muscular dystrophy patients whose mutations are amenable to an exon 51 skipping approach.
[PepGen, Inc.] |
|
|
|
|
| June 20 – 23, 2022
Sevilla, Spain |
|
|
|
|
|
| | Columbia University – New York, New York, United States |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | University of California, San Diego – La Jolla, California, United States |
|
|
|
| | Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| | Genentech, Inc. – South San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
